TSHA FY 2024 Earnings — Taysha Gene Therapies, Inc. Revenue & Financial Results | Market Cap Arena

TSHATaysha Gene Therapies, Inc.

$1B

FY 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$8M-46.1% YoY

Gross Profit

$8M100.0% margin

Operating Income

-$91M-1097.6% margin

Net Income

-$89M-1071.6% margin

EPS (Diluted)

$-0.36

Cash Flow

Operating Cash Flow

-$81M

Free Cash Flow

-$82M

Stock-Based Comp.

$13M

Balance Sheet

Total Assets

$160M

Total Liabilities

$89M

Stockholders' Equity

$72M

Cash & Equivalents

$139M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$8M	$15M	-46.1%
Gross Profit	$8M	$15M	-46.1%
Operating Income	-$91M	-$72M	-26.3%
Net Income	-$89M	-$112M	+20.0%